PREDAMIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PREDAMIDE (PREDAMIDE).
Predamide (a combination of prednisolone and sulfadimethoxine) exerts its effects via the corticosteroid anti-inflammatory action of prednisolone (inhibition of phospholipase A2, reduced prostaglandin synthesis) and the bacteriostatic action of sulfadimethoxine (competitive antagonism of para-aminobenzoic acid, inhibiting dihydropteroate synthase in folate synthesis).
| Metabolism | Prednisolone is primarily metabolized in the liver via 11β-hydroxysteroid dehydrogenase and cytochrome P450 3A4 (CYP3A4). Sulfadimethoxine is metabolized in the liver via acetylation and glucuronidation. |
| Excretion | Renal (80% as unchanged drug and metabolites, primarily glucuronide and sulfate conjugates), biliary/fecal (20%). |
| Half-life | Terminal elimination half-life: 12-15 hours. In hepatic impairment, half-life may extend to 20-25 hours; in renal impairment (CrCl <30 mL/min), half-life increases to 30-40 hours. |
| Protein binding | 98-99% bound primarily to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | 0.2-0.4 L/kg (approximately 14-28 L in a 70 kg adult), indicating distribution primarily in extracellular fluid. |
| Bioavailability | Oral: 75-85% (first-pass metabolism reduces bioavailability; food may decrease rate but not extent). |
| Onset of Action | Oral: 30-60 minutes. Intravenous: 5-10 minutes. |
| Duration of Action | Oral: 6-12 hours. Intravenous: 6-12 hours. Duration may be prolonged in hepatic or renal impairment. |
Prednisone 5 mg orally once daily, adjusted based on response.
| Dosage form | SUSPENSION/DROPS |
| Renal impairment | No specific GFR-based dose adjustments; use with caution in severe renal impairment. |
| Liver impairment | No formal Child-Pugh recommendations; avoid in severe hepatic impairment due to increased risk of toxicity. |
| Pediatric use | Weight-based dosing: 0.1-0.2 mg/kg/day orally up to a maximum of 5 mg/day. |
| Geriatric use | Initiate at lowest effective dose (e.g., 2.5 mg/day) and titrate slowly due to increased risk of adverse effects. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PREDAMIDE (PREDAMIDE).
| Breastfeeding | Prednisolone enters breast milk in low amounts (M/P ratio 0.1-0.2). Doses up to 40 mg/day safe; avoid high doses. Salicylamide: M/P ratio unknown; use with caution due to theoretical risk of Reye's syndrome and platelet dysfunction in neonate. |
| Teratogenic Risk | Predamide is a fixed-dose combination of prednisolone and salicylamide. Prednisolone is a corticosteroid. First trimester: increased risk of cleft palate (odds ratio 3.4). Second/third trimester: fetal adrenal suppression, intrauterine growth restriction, premature rupture of membranes. Salicylamide: potential for premature closure of ductus arteriosus (third trimester), oligohydramnios, neonatal hemorrhage. |
■ FDA Black Box Warning
WARNING: Sulfadimethoxine may cause severe hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, and agranulocytosis. Corticosteroids may mask signs of infection and increase susceptibility to secondary infections.
| Serious Effects |
Hypersensitivity to prednisolone, sulfonamides, or any component. Systemic fungal infections (for corticosteroids). Avoid in patients with porphyria, significant hepatic or renal impairment, or during pregnancy (especially first trimester for sulfonamides).
| Precautions | May exacerbate infections; avoid live vaccines. Prolonged corticosteroid use may lead to adrenal suppression, osteoporosis, and immunosuppression. Sulfadimethoxine may cause crystalluria, hemolytic anemia in G6PD deficiency, and photosensitivity. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure, blood glucose, fetal growth (ultrasound every 4 weeks after 24 weeks), amniotic fluid volume, fetal heart rate. Avoid use after 32 weeks due to ductus arteriosus closure risk. |
| Fertility Effects | Prednisolone may suppress ovulation and menstrual regularity; salicylamide no known direct effect. Both may impair male fertility in animal studies, but human data limited. |